R&D

Research and Development
We drive scientific research for the development of innovative drugs

We lead a network of public-private consortiums for Research, Development and Innovation (R&D+i) with more than 20 years of experience. These partnerships represent a synergistic collaboration model articulating the prestigious scientific tradition of the public sector with the capacity for technological development, production and marketing of the private sector.
We build partnerships with institutions including the National Council for Scientific and Technical Research (CONICET), the University of Quilmes (UNQ), the Ángel Roffo Oncology Institute, the University of Buenos Aires (UBA), the National Academy of Medicine, the Garrahan Hospital, and the National Industrial Technology Institute (INTI) of Argentina, as well as foreign universities.

We also partner with companies including RECOMBIO, Sinergium Biotech, Elea and Inmunova.
The consortiums are staffed by approximately 250 researchers, who engage in basic and applied research, developing products to treat cancer and other diseases.
One of the major accomplishments of this partnership effort was the finding of the first therapeutic vaccine against lung cancer, Racotumomab (Vaxira®). This product was developed in cooperation with the Molecular Immunology Center of La Habana (CIM) and Laboratorio Elea. It won an award at the National Innovation Contest, INNOVAR 2013 organized by the Ministry of Science, Technology and Productive Innovation of Argentina, in the Applied Research category.

The consortium earned the INNOVAR Award in 2015 to Innovation for the development and production of the first biosimilar monoclonal antibody in Latin America, NOVEX®.

A positive paradigm of collaboration


We work with public institutions to develop products that contribute to the health and wellbeing of patients.

Public-Private Consortium